Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 3/20 | 0.88 |
| ▸ | HTT | P42858 | 2/20 | 0.88 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.88 |
| ▸ | POLB | P06746 | 1/20 | 0.88 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.79 |
| ▸ | MEN1 | O00255 | 3/20 | 0.79 |
| ▸ | GAA | P10253 | 2/20 | 0.76 |
| ▸ | LMNA | P02545 | 2/20 | 0.76 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.76 |
| ▸ | TSHR | P16473 | 1/20 | 0.72 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.72 |
| ▸ | NPC1 | O15118 | 1/20 | 0.67 |
| ▸ | RAB9A | P51151 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3303527 | 1.00 | PKM (0.88) | PKMHTTALDH1A1POLBKMT2A | |
| SCHEMBL4537086 | 1.00 | PKM (0.88) | PKMHTTALDH1A1POLBKMT2A | |
| SCHEMBL8200466 | 1.00 | PKM (0.88) | PKMHTTALDH1A1POLBKMT2A | |
| SCHEMBL565301 | 1.00 | PKM (0.88) | PKMHTTALDH1A1POLBKMT2A | |
| SCHEMBL8203532 | 1.00 | PKM (0.88) | PKMHTTALDH1A1POLBKMT2A | |
| SCHEMBL3971438 | 1.00 | PKM (0.88) | PKMHTTALDH1A1POLBKMT2A | |
| SCHEMBL10724066 | 1.00 | PKM (0.88) | PKMHTTALDH1A1POLBKMT2A | |
| SCHEMBL8502340 | 0.94 | PKM (1.00) | PKMHTTALDH1A1POLBKMT2A | |
| SCHEMBL8583228 | 0.94 | PKM (1.00) | PKMHTTALDH1A1POLBKMT2A | |
| SCHEMBL7953663 | 0.94 | PKM (1.00) | PKMHTTALDH1A1POLBKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 277 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110256368-B | Cycloaddition method of amidine compound and aziridine compound | 山西省产品质量监督检验研究院 | 2022-08-19 | — | — | CN | claimed |
| EP-2368896-A1 | Mono-indenyl transition metal compounds and polymerization therewith | ExxonMobil Chemical Patents Inc. (US) | 2011-09-28 | — | — | EP | claimed |
| US-20110213109-A1 | Mono-Indenyl Transition Metal Compounds and Polymerization Therewith | EXXONMOBIL CHEMICAL PATENTS INC. | 2011-09-01 | — | — | US | claimed |
| EP-1985624-A2 | Single step method of radiofluorination of biologically active compounds or biomolecules | Bayer Schering Pharma Aktiengesellschaft (DE) | 2008-10-29 | — | — | EP | claimed |
| EP-0655656-A1 | Toner for developing electrostatic image | TOMOEGAWA PAPER CO. LTD. (JP) | 1995-05-31 | — | — | EP | claimed |
| EP-0115771-B1 | Dense star polymers and a process for producing dense star polymers | DOW CHEMICAL CO (US) | 1995-03-01 | — | — | EP | claimed |
| EP-0341498-B1 | Adsorbent comprising a coating of polyethyleneimine derivatized with a hydrophobic group, its production and its use for immunoassays and separations | DU PONT (US) | 1994-05-18 | — | — | EP | claimed |
| US-3983564-A | Image recording member | CANON KABUSHIKI KAISHA (JA) | 1976-09-28 | — | — | US | claimed |
| US-12624020-B2 | Compositions and methods for preparing and using azetidines | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2026-05-12 | — | — | US | disclosed |
| EP-4467631-B1 | MIXTURE COMPRISING EUROPIUM-ORGANIC COORDINATION COMPOUND AND METHOD FOR PRODUCING THE SAME | BEEOLED GMBH (DE) | 2025-05-14 | — | — | EP | disclosed |
| US-20250093263-A1 | FRET-BASED ASSAYS | THE GENERAL HOSPITAL CORPORATION | 2025-03-20 | — | — | US | disclosed |
| US-20250084303-A1 | Complexes and Ligands | THE GENERAL HOSPITAL CORPORATION | 2025-03-13 | — | — | US | disclosed |
| EP-4512815-A2 | MANGANESE CHELATE ISOMERS | GE Healthcare AS (NO) | 2025-02-26 | — | — | EP | disclosed |
| CN-119241533-A | Preparation method of tetrahydro-gamma-carboline | 湖北科技学院 | 2025-01-03 | — | — | CN | disclosed |
| EP-0244320-A1 | Process for the photochemical cleavage of nucleic acids by 2,7-diazapyrenium dications, and diazapyrene derivatives | CIS BIO INTERNATIONAL (FR) | 1987-11-04 | — | — | EP | disclosed |
| EP-0212085-A2 | Salt resistant polyamide composition | AlliedSignal Inc. (US) | 1987-03-04 | — | — | EP | disclosed |
| US-4631337-A | Hydrolytically-stable dense star polyamine | THE DOW CHEMICAL COMPANY (US) | 1986-12-23 | — | — | US | disclosed |
| US-4587329-A | Dense star polymers having two dimensional molecular diameter | THE DOW CHEMICAL COMPANY (US) | 1986-05-06 | — | — | US | disclosed |
| US-4479901-A | Fluorination of carbanions with N-fluoro-N-alkylsulfonamides | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1984-10-30 | — | — | US | disclosed |
| US-3983564-A | Image recording member | CANON KABUSHIKI KAISHA (JA) | 1976-09-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250093263-A1 | FRET-BASED ASSAYS | TARBP1, GTPBP4, TERF2IP | PKM 3807/4885HTT 1710/4885ALDH1A1 4326/4885 |
| US-20250084303-A1 | Complexes and Ligands | BID, CLTB, NECTIN4 | PKM 3725/4885HTT 2222/4885ALDH1A1 3131/4885 |
| US-12624020-B2 | Compositions and methods for preparing and using azetidines | PRKAR2A, GRK2, GRK6 | PKM 4610/4885HTT 4548/4885ALDH1A1 4361/4885 |
| US-20110213109-A1 | Mono-Indenyl Transition Metal Compounds and Polymerization Therewith | ICMT, TERT, PIN1 | PKM 1016/4885HTT 1071/4885ALDH1A1 902/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.